|
|||||||||||||
|
|||||||||||||
|
|
|||||||||||||
News & Events
- FDA debates use for Amgen's Xgeva
-
06 FEB, 2012 10:18 EST Reuters
FDA staff unsure about new use for Amgen's XgevaReviewers from the U.S. Food and Drug Administration said on Monday that they were not sure whether Amgen Inc's Xgeva bone drug should be approved for a wider use of delaying the spread of cancer to the bone.
The injectable drug is already approved to prevent fractures...
- Orexigen obesity drug trial ready
-
06 FEB, 2011 10:28 ET Reuters
Orexigen, FDA agree on trial design for obesity drug
Orexigen Therapeutics Inc said it reached an agreement with U.S. health regulators on the design of a heart-safety trial required for the approval of its experimental obesity drug.
The biopharmaceutical company plans to enroll about 10,000...
- Positive Ph3 Results for Merck
-
06 FEB, 2012 09:44 ET Reuters
Merck Achieves Positive Results In Phase 3 Trials Of Insomnia Drug
Merck & Co. said it achieved positive results in Phase 3 trials of its experimental insomnia treatment, a key drug in the pharmaceutical giant's pipeline.
The company is working to bring successful new drugs to market to help offset the loss later...
Compliance starts here.
Find out more about the full suite of services TSS offers - request an electronic copy of the TSS brochure today.
Brochure request form